We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





LumiraDx Demonstrates Transformative Tests and Technologies

By LabMedica International staff writers
Posted on 13 Nov 2023
Print article
Image: The innovative, next generation LumiraDx Point of Care Diagnostic Platform (Photo courtesy of LumiraDx)
Image: The innovative, next generation LumiraDx Point of Care Diagnostic Platform (Photo courtesy of LumiraDx)

LumiraDx (London, UK) is presenting its innovative, next-generation point-of-care diagnostics Platform and broad test menu alongside its Fast Lab Solutions at MEDICA 2023.

The LumiraDx Platform is an innovative, next-generation point-of-care system that combines a small, portable instrument, advanced low-cost test strip, and seamless digital connectivity. Its proprietary technology enables it to deliver exceptional point-of-care clinical performance while being simple and easy to use. LumiraDx offers various tests that run on the highly portable LumiraDx Platform, such as the LumiraDx NT-proBNP test which is a quantitative, fingerstick blood assay designed for near-patient testing with lab-comparable results in 12 minutes. It is the only fingerstick NT-proBNP test currently commercially available. The rapid microfluidic immunofluorescence assay can aid in the diagnosis of congestive heart failure (CHF).

LumiraDx also offers its highly sensitive C-Reactive Protein (CRP) point-of-care antigen test that runs on the portable LumiraDx platform which weighs just over a kilogram. The point of care CRP test can be used in multiple clinical settings to help reduce unnecessary antibiotic prescribing that leads to antimicrobial resistance. From a tiny sample of finger-prick blood, the CRP test gives results within four minutes. Additionally, LumiraDx’s HbA1c test for professional use across multiple care settings is used alongside the LumiraDx Platform. The test monitors known diabetic patients’ HbA1c levels and also serves as an aid in screening and identifying patients who may be at risk for developing diabetes. Providing results in less than seven minutes from sample application, the test allows improved efficiency and convenience with on-the-spot diabetes screening and monitoring at the patient’s side.

At MEDICA 2023, LumiraDx is highlighting its LumiraDx INR Test which is an enzyme kinetic assay based on Thrombin activity. The coagulation cascade is activated by the test reagents and INR is calculated from the measured PT-time. Haematocrit is also measured on the strip to ensure patients are within the 25-55% range. The accuracy of the LumiraDx INR Test is comparable to the ACL Elite lab reference method. Another test that supports confident decisions at the point of care with the LumiraDx Platform is the LumiraDx D-Dimer Test which is a rapid microfluidic immunoassay for quantitative determination of D-Dimer. It is the only D-Dimer Test providing fast, accurate, quantitative results in just 6 minutes from a fingerstick blood sample.

Related Links:
LumiraDx 

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Gold Member
Troponin T QC
Troponin T Quality Control
New
RNA Isolation Kits
RNeasy Plus Kits for RNA Isolation
New
Anti-Thyroglobulin Reagent
Anti-TG Reagent Kit

Print article

Channels

Immunology

view channel
Image: Example image of the high-throughput microscopy method used in the study, showing immune cells stained with different fluorescence markers (Photo courtesy of Felix Kartnig/CeMM, MedUni Vienna)

Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies

Rheumatoid arthritis is the most common inflammatory joint disorder, with women three times as likely to suffer from the condition as men. Treatment advances made over the past decades have led to the... Read more

Microbiology

view channel
Image: RNA sequencing directly from whole blood aims to expand access to LRTI testing (Photo courtesy of CARB-X)

Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood

Pneumonia and lower-respiratory-tract infections (LRTIs) are among the top causes of illness and death globally, particularly in vulnerable populations such as the elderly, young children, and immunocompromised... Read more

Pathology

view channel
Image: The new method uses DNA sequencing to measure metabolites (Photo courtesy of 123RF)

New Metabolite Detection Method Using DNA Sequencing Could Transform Diagnostics

Metabolites play a vital role as biomarkers that provide insights into our health, and when their levels go awry, it can lead to diseases such as diabetes and phenylketonuria. Quantifying metabolites remains... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.